Gilead Sciences’ $3.6 Billion HIV Drug Antitrust Case

Proskauer and Kirkland & Ellis secured a decisive victory for Gilead Sciences, Inc. in a $3.6 billion antitrust case on allegations that the pharmaceutical company struck…

This content is for Standard 1 Year members only.
Login Join Now

Vehicle Accessories’ Acquisition of Maxton Group

Lumana’s $24 Million Series Seed Financing

Strattam Capital’s $308 Million Closing of its Third Flagship Fund

Grupo De Inversiones Suramericana (Grupo SURA)’s $500 Million Loan

G Mining Ventures Corp.’s Combination With Reunion Gold Corporation

AES Brasil Operacoes’ R$600 Million Debentures Offering

TokenEx’s Partnership Agreement with IXOPAY

Dufry One B.V. (Avolta AG)’s €500 Million Bonds Offering

iTaxi.pl’s Financing Round

KOKO Networks Limited’s Financing Round

India Vehicle Finance’s Notes Offering

Al-Arafa’s Demerger into Concrete Fashion Group and GTEX

SC Ventures’ $100 Million Joint Venture With SBI Holdings

GreenCorp’s Acquisition of Emad Bakeries

MedOne’s Agreement with Shikun and Binui Energy

Apple South Asia’s Investment in Clean Max Hyperion Power

ReNew Energy Global’s Transaction Agreement with JERA

AG&P LNG Marketing’s Investment Round

Securities Regulation Partner Emily Gordy Joins King & Spalding in Washington, D.C.

Labor and Employment Lawyer Sydney Jones Lampard Joins King & Spalding in Washington, D.C.

Hefesto Asesores continues to consolidate its position in the International Private Equity and Venture Capital market, with the formation of Hefesto Global

The Distinctive Character Of The ‘Vespa’ Is No Longer In Question

Cultural Heritage Sites With Restrictions On Intended Use: The Council of State Acknowledges That This Power Lies In the Hands Of The Ministry Of Culture

The Italian Revenue Agency Qualifies Directors’ Reversible Remuneration For The Purposes Of Double Taxation Agrements.

Securities Regulation Partner Emily Gordy Joins King & Spalding in Washington, D.C.

Labor and Employment Lawyer Sydney Jones Lampard Joins King & Spalding in Washington, D.C.

Paul Hastings Adds Premier Private Equity Buyout Team

Gilead Sciences’ $3.6 Billion HIV Drug Antitrust Case

Author: Laura Testa